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ABSTRACT
Objectives The rarity of early diffuse cutaneous
systemic sclerosis (dcSSc) makes randomised controlled
trials very difﬁcult. We aimed to use an observational
approach to compare effectiveness of currently used
treatment approaches.
Methods This was a prospective, observational cohort
study of early dcSSc (within three years of onset of skin
thickening). Clinicians selected one of four protocols for
each patient: methotrexate, mycophenolate mofetil
(MMF), cyclophosphamide or ‘no immunosuppressant’.
Patients were assessed three-monthly for up to
24 months. The primary outcome was the change in
modiﬁed Rodnan skin score (mRSS). Confounding by
indication at baseline was accounted for using inverse
probability of treatment (IPT) weights. As a secondary
outcome, an IPT-weighted Cox model was used to test
for differences in survival.
Results Of 326 patients recruited from 50 centres,
65 were prescribed methotrexate, 118 MMF, 87
cyclophosphamide and 56 no immunosuppressant.
276 (84.7%) patients completed 12 and 234 (71.7%)
24 months follow-up (or reached last visit date). There
were statistically signiﬁcant reductions in mRSS at
12 months in all groups: −4.0 (−5.2 to −2.7) units for
methotrexate, −4.1 (−5.3 to −2.9) for MMF, −3.3
(−4.9 to −1.7) for cyclophosphamide and −2.2 (−4.0
to −0.3) for no immunosuppressant (p value for
between-group differences=0.346). There were no
statistically signiﬁcant differences in survival between
protocols before (p=0.389) or after weighting
(p=0.440), but survival was poorest in the no
immunosuppressant group (84.0%) at 24 months.
Conclusions These ﬁndings may support using
immunosuppressants for early dcSSc but suggest that
overall beneﬁt is modest over 12 months and that better
treatments are needed.
Trial registration number NCT02339441.
INTRODUCTION
The diffuse cutaneous subtype of systemic sclerosis
(dcSSc) is rare (SSc incidence is around 10–20/
million/year,1 of whom approximately 25% will
have diffuse disease) but carries high morbidity and
mortality due to early internal organ involvement
and rapidly progressive, painful skin thickening.
Also, 5-year and 10-year survival rates, although
improving, are in the order of 68% and 50%,
respectively.2 3
At present, there is no drug known to favourably
inﬂuence disease course. Randomised controlled
trials (RCTs) have historically been confounded by
disease rarity (only small numbers of patients are
recruited, often over long periods) and strict entry
criteria meaning that severe cases are often
excluded.4 These strict criteria further restrict
sample sizes and limit generalisability. Therefore,
although RCTs represent a gold standard for asses-
sing drug efﬁcacy, results may not be applicable to
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real-life clinical settings.5 Small trials run the risk of being
underpowered, thus potentially yielding false-negative results.6
The past three decades have seen a number of promising treat-
ments for early dcSSc failing to meet efﬁcacy end points in
RCTs: examples include methotrexate (multinational, 71
patients)7 and anti-transforming growth factor β1 antibody
therapy (multinational, 45 patients).8
A further difﬁculty in recruiting into RCTs of early dcSSc is
that many clinicians have reservations about placebo therapy in
a potentially life-threatening disease and favour immunosup-
pression, consistent with the European League Against
Rheumatism (EULAR) recommendations, which advocate
methotrexate for skin manifestations9 in early dcSSc, although
this agent has been shown to be of only limited efﬁcacy.7
Immunosuppressants are potentially hazardous, especially in
patients prone to internal organ disease and infection.
Against this background, our aim was to compare, using an
observational approach, the effectiveness of standard treatment
approaches (mainly immunosuppressant treatments but includ-
ing a ‘no immunosuppressant’ option to reﬂect that some
patients or clinicians may choose this approach) in the early
management of patients with dcSSc, capturing entry and
outcome data in a systematic way. Modern statistical approaches
allow robust interrogations of prospective observational studies,
as an adjunct to, or even substitute for, RCTs in rare diseases,10
although the potential of these novel approaches has not yet
been realised.11
METHODS
Study design
The European Scleroderma Observational Study (ESOS) was a
prospective, observational cohort study (ClinicalTrials.gov iden-
tiﬁer: NCT02339441), in which standardised data were col-
lected at study entry and at follow-up visits, and entered
electronically by investigators at each centre into an electronic
case record form. All data were checked by the project coordin-
ator and any inconsistencies were discussed with the chief inves-
tigator and (if appropriate) the local principal investigator. The
main inclusion criteria were early dcSSc (skin involvement prox-
imal to elbow, knee, face, neck12 and within three years of the
onset of skin thickening) and age >18 years. Exclusion criteria
were previous stem cell transplantation, previous immunosup-
pressant treatment for >4 months or use of any immunosup-
pressant drug other than methotrexate, mycophenolate mofetil
(MMF) or cyclophosphamide within the month prior to study
entry.
Clinicians selected the protocol of their choice for each
patient. The recommended treatment protocols, as decided by
the Steering Committee to reﬂect international best clinical prac-
tice, were
1. Methotrexate (oral or subcutaneous with a target dose of
20–25 mg weekly).
2. MMF (500 mg twice daily for 2 weeks increasing to 1 g
twice daily).
3. Cyclophosphamide.
Possible regimens included:
i. Intravenous. Minimum monthly dose 500 mg/m2 with a
recommended duration of 6–12 months.
ii. Oral. 1–2 mg/kg/day with a recommended duration of
12 months. Patients treated with cyclophosphamide were
then usually ‘transferred’ to a maintenance immunosup-
pressive drug (methotrexate, MMF or azathioprine) as
per the treating clinician’s choice.
4. No immunosuppressant treatment, to give the option of
including patients in whom immunosuppression was not felt
indicated or appropriate (or declined by the patient).
Patients were assessed at baseline, with subsequent visits
scheduled three-monthly for 24 months (or between 12 and
24 months for those patients recruited after September 2013).
To have 80% power to detect a difference between two treat-
ment arms of ﬁve modiﬁed Rodnan skin score (mRSS) units at
12 months would require 63 patients per protocol. Allowing
20% loss to follow-up, and varying numbers recruited to the
different protocols, recruitment target was 316 patients.
Patients
Patients were recruited between July 2010 and September 2014.
Demographic characteristics including age, gender, smoking
habit, ethnicity, antibody status (anti-topoisomerase-1
(anti-Scl70), anti-RNA III polymerase, anticentromere) and pres-
ence of visceral organ involvement were recorded for all
patients. The algorithms to determine the presence of different
types of organ involvement are summarised in online
supplementary table S1.
Outcome measures
The primary outcome measure, assessed at each visit, was the
change in mRSS over time. All mRSS assessments were per-
formed by those experienced in skin scoring. The mRSS is
assessed clinically at 17 body sites on a 0–3 scale (maximum
score 51) and measures the extent of skin thickening.13 It is the
most commonly used primary outcome measure in RCTs of
dcSSc,4 7 8 reﬂecting disease severity and predicting mortality.14
All other outcomes/recorded variables were mainly part of
routine clinical practice and are summarised in online
supplementary table S2. Secondary end points included pulmon-
ary function (forced vital capacity (FVC: % predicted) and
carbon monoxide diffusing capacity (DLCO: % predicted)),
quality of life15–18 (including the Health Assessment
Questionnaire Disability Index (HAQ-DI)15 and Cochin Hand
Function Scale18), occurrence of side effects and survival.
Statistical analysis
In an observational study, patient characteristics differ between
groups and any differences in outcomes might be driven by
those characteristics rather than the treatments (confounding by
indication). In each of the analyses (for the different outcome
measures), all variables associated with the outcome were con-
sidered as confounders.19 20
Differences between protocols at baseline
Kruskal-Wallis test was applied for continuous variables and
Fisher’s test for categorical variables.
Inﬂuence of baseline characteristics on mRSS at baseline
and over time
The association between baseline variables and mRSS was
assessed by simple linear regressions, entering each characteristic
separately as a predictor of mRSS. To examine how each vari-
able affected the progression of mRSS, the regression equation
was modiﬁed by adding a term for time and its interaction with
the baseline predictor value.
Differences in the changes between groups for all outcomes
Inverse probability of treatment (IPT) weights equalise the dis-
tributions of confounders between the treatment groups, thus
removing confounding by indication.21 Treatment probabilities
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were computed using multinomial logistic regressions, with the
baseline values of the selected confounders as predictors.22
Censoring weights rebalance the data such that the distributions
of confounders remain unchanged throughout the study. For
each observation, the probability of remaining uncensored given
the baseline values of the confounders, the initial protocol and a
cubic spline for time was calculated using a pooled logistic
regression model.23 Multiplying both weights yielded the IPT
and inverse probability of censoring (IPTC) weights. Weights
>20 were truncated at that value.24
Treatment effects were assessed using IPTC-weighted linear
regression models, which include an intercept, a time term, indi-
cator variables for treatment groups and interactions between
time and treatments. The model followed an intention-to-treat
approach. Differences in the interaction terms reﬂected differ-
ences in the evolution of outcome.
Cochin hand function data were log-transformed (after
adding one to each value) to correct for a highly left-skewed dis-
tribution. CIs for the difference of logs were back-transformed,
yielding a percentage difference between predicted baseline and
12-month levels.
Because of missing data at baseline for confounders, multiple
imputation by chained equations was applied with STATA
V.13.1. Imputations were performed separately for each differ-
ent outcome model. Moreover, each analysis was restricted to
the subset of patients with available outcome data at baseline.
Survival analysis
Kaplan-Meier curves, adjusted using IPT weights, provide esti-
mates of the cumulative probability of surviving in each of the
protocols. An IPT-weighted Cox regression, including indicator
variables for the protocols, was used to test for differences in
survival between protocols. Both overall and adverse event-free
survival were examined.
RESULTS
In total, 326 patients from 50 centres (19 countries) were
recruited into the study (ﬁgure 1): 160 from mainland Europe
and the Middle East, 134 from the UK, 15 from Australia and
17 from North America (six centres from Australia and North
America joined after the initial recruitment wave). Not being a
randomised study, the number of patients starting on each
protocol differed: 65 (19.9%) methotrexate, 118 (36.2%)
MMF, 87 (26.7%) cyclophosphamide and 56 (17.2%) no
immunosuppressant treatment. Median (IQR) doses are shown
in online supplementary table S3.
Baseline characteristics of patients
The median mRSS (21, IQR 16–27) and its distribution did not
differ across all four treatment groups (p=0.306) (table 1).
There were signiﬁcant differences between treatment groups in
gender (patients in the cyclophosphamide group less likely to be
female, p=0.003) and duration of skin thickening (the ‘no
immunosuppressant’ group had the longest, p=0.001). Also,
patients in the cyclophosphamide group were more likely to
have had previous immunosuppression (p=0.007) or steroid
treatment (p=0.001). At baseline, 94 (28.8%) patients were
taking oral corticosteroids, with a median dose of 10 mg/day
(range 2.5–60 mg/day).
Organ involvement
There were signiﬁcant differences between groups for presence
of pulmonary ﬁbrosis, cardiac, renal and muscle involvement.
Patients on cyclophosphamide were more likely to have
pulmonary ﬁbrosis (p=0.036 across groups) or cardiac involve-
ment (p=0.009 across groups). Patients in the ‘no immunosup-
pressant’ group were more likely to have renal involvement
(p=0.039), and the methotrexate group had more frequent
muscle involvement (p=0.002).
Functional ability
Scores for the HAQ-DI, Functional Assessment of Chronic
Illness Therapy (FACIT) fatigue and Short-Form 36 (SF36)
physical and mental indexes did not differ signiﬁcantly between
groups. However, there were signiﬁcant differences across
groups in the cochin hand function scale (CHFS), which was
poorest in the cyclophosphamide group (p=0.025).
Concomitant medications
As anticipated in a study of patients with early dcSSc, there was
substantial use of concomitant medications (see online
supplementary table S4).
Progression through the study
Figure 1 shows how patients progressed through the study.
Overall, 276 patients (84.7%) remained in the study at
12 months of follow-up and 234 (71.7%) completed 24 months
(or reached the last study visit date of 30 September 2015).
Changes in protocol
A total of 60 (18.4%), 12 (3.7%) and 1 (0.3%) patients
changed protocol one, two or three times during the study.
Among patients still in the study, adherence to initial protocol at
24 months for the different cohorts was 76.2% (methotrexate),
79.7% (MMF), 79.2% (cyclophosphamide) and 73.3% (no
immunosuppressant) (see online supplementary ﬁgure S1). In
the no immunosuppressant cohort, 10 out of 56 patients com-
menced an immunosuppressant (ﬁgure 1).
Withdrawals and deaths
In total, 35 patients (10.7%) died and 42 (12.9%) withdrew
from the study (including lost to follow-up). Of the 35 deceased
patients, 31 cases were primarily attributed to SSc-related causes
(26 most likely primarily cardiorespiratory, 2 renal crises, 2
gastrointestinal (one aspiration) and 1 peritonitis (on peritoneal
dialysis following renal crisis)), 3 died of cancer (1 nasopharyn-
geal, 1 rectal, 1 colorectal) and in 1 case the cause was
unknown.
Inﬂuence of baseline variables on the initial skin score
and on skin score trajectory
Table 2 summarises the effect of different characteristics on the
initial mRSS and its subsequent trajectory, as analysed with
linear regression.
Using the associations described by table 2, the confounders
identiﬁed for the skin score were age, duration of skin thicken-
ing, current or previous steroid use, anti-topoisomerase,
anti-RNA polymerase III, pulmonary ﬁbrosis, pulmonary hyper-
tension, cardiac, renal and muscle involvement, as well as
HAQ-DI, Cochin hand function and FACIT fatigue scores (see
online supplementary table S5 for lists of confounders and
online supplementary tables S6– S13 for each model’s confoun-
der selection process).
Changes in skin score over time in the different treatment
groups
The mean change in mRSS after 12 and 24 months was −2.9 and
−6.7 units. Based on a weighted regression model, there were
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Figure 1 Progression of patients through the study.
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Table 1 Baseline characteristics and differences between protocols
Characteristic
Protocol 1
Methotrexate
n=65
Protocol 2
Mycophenolate
mofetil, n=118
Protocol 3
Cyclophosphamide
n=87
Protocol 4
No
immunosuppressant
n=56
P
Value*
Total
n=326
Missing at
baseline,
no. (%)
Age, years 52.5
(41.5–61.1)
50
(40.7–61.1)
54.1
(45.7–60.5)
52.3
(42.3–60.3)
0.324 52.3
(43–60.8)
0
(0%)
Female, no. (%) 50
(76.9%)
94
(79.7%)
49
(56.3%)
40
(71.4%)
0.003 233
(71.5%)
0
(0%)
Months since onset of skin thickening 10.3
(5.5–20.8)
12.6
(7.8–21.8)
10.2
(5.9–14.5)
16.5
(8.7–27)
0.001 11.9
(7–21)
18
(5.5%)
Years since onset of first non-Raynaud’s
manifestation
1.3
(0.7–2.1)
1.4
(0.9–2)
1.0
(0.6–1.4)
1.7
(0.9–2.5)
0.001 1.2
(0.8–2)
6
(1.8%)
Years since onset of Raynaud’s
phenomenon
1.3
(0.7–2.5)
1.9
(1.1–3.1)
1.4
(0.9–2.4)
2.2
(1.1–3.7)
0.014 1.7
(1–2.9)
22
(6.7%)
Previous immunosuppressant use, no. (%)† 3
(4.6%)
5
(4.2%)
15
(17.2%)
3
(5.4%)
0.007 26
(8%)
0
(0%)
Current or previous steroid use, no. (%) 33
(50.8%)
39
(34.2%)
51
(58.6%)
18
(32.1%)
0.001 141
(43.8%)
4
(1.2%)
Current smoker (%) 11
(16.9%)
17
(15.3%)
18
(21.7%)
11
(20.8%)
0.646 57
(18.3%)
14
(4.3%)
History of cancer, no. (%) 5
(7.8%)
4
(3.4%)
4
(4.7%)
7
(12.5%)
0.121 20
(6.2%)
4
(1.2%)
Caucasian, no. (%) 54
(83.1%)
92
(78.0%)
77
(88.5%)
49
(87.5%)
0.201 272
(83.4%)
0
(0%)
mRSS (0–51) 21
(17–24)
21
(16–27)
22
(17–29)
20
(15.5–26)
0.306 21
(16–27)
0
(0%)
Haemoglobin (g/L) 127
(118–136)
126
(118–137)
130
(116–140)
130
(118–139)
0.721 128
(118–137)
13
(4%)
White blood count (×109/L) 7.7
(6.7–9.4)
7.9
(6.4–9.5)
8.9
(7.3–10.6)
8.0
(6.7–9.4)
0.029 8
(6.8–9.9)
14
(4.3%)
Platelets (×109/L) 300
(254–337)
298
(246–370)
309
(259–359)
281
(250–337)
0.459 298
(253–358)
15
(4.6%)
ESR (mm/hour) 17
(10–29)
18
(8–30)
21
(9–48)
20
(10–35)
0.341 18
(8–34)
77
(23.6%)
CRP (mg/L) 4.0
(2.2–7.5)
5.0
(1.1–11)
5.9
(3.2–20.0)
4.8
(3.0–11.7)
0.026 5
(2.1–11.8)
90
(27.6%)
Anti-topoisomerase (anti-Scl70), no. (%) 20
(31.3%)
49
(42.6%)
39
(45.3%)
18
(33.3%)
0.228 126
(39.5%)
7
(2.1%)
Anti-RNA polymerase III, no. (%) 9
(18.8%)
23
(23.2%)
9
(13.0%)
9
(19.6%)
0.433 50
(19.1%)
64
(19.6%)
Anticentromere, no. (%) 9
(14.1%)
6
(5.4%)
4
(4.7%)
3
(5.7%)
0.147 22
(7%)
12
(3.7%)
Organ involvement
Pulmonary fibrosis, no. (%) 8
(12.3%)
13
(11%)
21
(24.1%)
5
(8.9%)
0.036 47
(14.4%)
0
(0%)
FVC (% predicted) 93.7
(81–106)
90
(75–102)
82.5
(68.5–96.5)
90
(75–100)
0.026 89
(75–102)
19
(5.8%)
DLCO (% predicted) 73
(62–83)
64.5
(48–77)
57
(41–73)
64
(52–75)
<0.0005 64
(50–78)
35
(10.7%)
Pulmonary hypertension, no. (%) 4
(6.3%)
7
(5.9%)
10
(11.5%)
5
(8.9%)
0.488 26
(8%)
1
(0.3%)
sPAP or RVSP (mm Hg)‡ 27
(23–32)
27
(20–33)
30
(23–37)
27
(23–35)
0.472 29
(21–34)
124
(38%)
Cardiac involvement, no. (%) 5
(7.7%)
8
(6.8%)
19
(21.8%)
7
(13.0%)
0.009 39
(12%)
2
(0.6%)
Renal involvement, no. (%)§ 1
(1.5%)
13
(11%)
10
(11.5%)
8
(14.3%)
0.039 32
(9.8%)
0
(0%)
eGFR (mL/min) 90
(63–90)
84.5
(60–90)
90
(60–90)
80
(60–90)
0.339 85
(60–90)
92
(28.2%)
Renal crisis 0
(0%)
8
(6.8%)
4
(4.6%)
4
(7.1%)
0.110 16
(4.9%)
0
(0%)
Plasma creatinine (μmol/L) 63.5
(55–72)
69
(55–83)
64.5
(53–86)
64
(56–77)
0.422 65
(55–79.5)
70
(21.5%)
Continued
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statistically signiﬁcant reductions in mRSS in all four treatment
groups at 12 months (−4.0 (−5.2 to −2.7) units for methotrexate,
−4.1 (−5.3 to −2.9) for MMF, −3.3 (−4.9 to −1.7) for cyclo-
phosphamide and −2.2 (−4.0 to −0.3) for the no immunosup-
pressant group), but the differences between treatments were not
signiﬁcant (p=0.346) (table 3 and ﬁgure 2).
Changes in secondary outcomes over time in the different
treatment groups
Lung function
After adjusting for potential confounders, the change rates of
FVC and DLCO were not signiﬁcantly different in the four
treatment groups (p=0.460 and 0.505) (table 3).
However, in a subset of patients with pulmonary ﬁbrosis or
suspected pulmonary ﬁbrosis (cases conﬁrmed on high-
resolution CT (HRCT) irrespective of FVC or DLCO, or with
one of the following if HRCT not performed: FVC or DLCO
under 55% predicted or deﬁnite bibasal shadowing on X-ray),
there was a signiﬁcant difference in the change rate of FVC over
time (p=0.035). Patients initially prescribed cyclophosphamide
demonstrated 7.4% absolute increase in FVC (% predicted)
compared with 2.0% decrease for methotrexate, 3.2% increase
for MMF and 4.0% increase for the ‘no immunosuppressant’
group (table 3).
Functional ability and hand function
Changes over time for the HAQ-DI and CHFS did not differ
between protocols (p=0.130 and 0.073), regardless of adjusting
(table 3).
Development of internal organ involvement
This is described in online supplementary ﬁgure S2.
Comparison of survival between treatment protocols
Survival was lowest in the no immunosuppressant group at both
12 and 24 months but differences between protocols were not
statistically signiﬁcant either before (p=0.389) or after weight-
ing (p=0.440). In the adjusted model, at 24 months, those in
the no immunosuppressant group had a predicted survival rate
of 84.0% compared with 94.1% for methotrexate, 88.8% for
MMF and 90.1% for cyclophosphamide (ﬁgure 3). Patients
with lung involvement (pulmonary ﬁbrosis and/or hypertension)
at baseline had signiﬁcantly poorer survival than those without:
at 24 months, their predicted survival rate was 74.6% versus
91.7% (p<0.0005) and similarly for cardiac involvement,
71.6% versus 90.7% (p<0.0005).
Adverse effects
Of the 75, 182 and 101 patients who were ever on methotrex-
ate, MMF or cyclophosphamide, respectively, 29 (38.7%), 40
(22.0%) and 23 (22.8%) were reported to have had side effects,
necessitating drug discontinuation in 9 (12.0%), 14 (7.7%) and
5 (4.5%) patients, respectively. A survival analysis on protocol
exits due to adverse effects showed no differences in the toler-
ability of the three treatments (p=0.212) (see online
supplementary ﬁgure S3).
DISCUSSION
Our main ﬁndings were, ﬁrst, that there were no signiﬁcant dif-
ferences in outcome between the four treatment protocols
(methotrexate, MMF, cyclophosphamide, no immunosuppres-
sion), although there may be a signal in favour of immunosup-
pression for early dcSSc. Although skin score improved in all
treatment groups, this was least in the no immunosuppressant
category, who also had the highest mortality. Second, ESOS
Table 1 Continued
Characteristic
Protocol 1
Methotrexate
n=65
Protocol 2
Mycophenolate
mofetil, n=118
Protocol 3
Cyclophosphamide
n=87
Protocol 4
No
immunosuppressant
n=56
P
Value*
Total
n=326
Missing at
baseline,
no. (%)
Any GI involvement, no. (%) 25
(38.5%)
32
(27.1%)
30
(34.5%)
26
(46.4%)
0.078 113
(34.7%)
0
(0%)
Muscle involvement, no. (%) 12
(18.5%)
9
(7.6%)
10
(11.5%)
0
(0%)
0.002 31
(9.5%)
0
(0%)
Current digital ulcers 10
(15.4%)
17
(14.4%)
17
(19.5%)
11
(19.6%)
0.705 55
(16.9%)
0
(0%)
Patient questionnaire data
HAQ-DI (0–3) 1.1
(0.4–1.8)
1
(0.5–1.6)
1
(0.4–1.9)
0.7
(0.1–1.5)
0.400 1
(0.4–1.8)
19
(5.8%)
FACIT fatigue score (0–52) 33
(21.5–42.5)
30
(20–37)
31
(17–40)
37
(21–44)
0.165 31
(20–41)
16
(4.9%)
SF36 physical score (0–100) 39.2
(30.9–45.1)
36.4
(30.8–43)
36
(27.2–44.5)
39.2
(32–48.4)
0.203 37.4
(29.9–45)
15
(4.6%)
SF36 mental score (0–100)¶ 37.2
(33.3–44)
36.8
(32.2–41.9)
39.5
(35.7–44.7)
40.8
(35.9–44.1)
0.029 38.3
(34.3–44)
15
(4.6%)
Cochin hand function score (0–90) ** 11.5
(2–30.5)
10
(4–24)
16
(5–40)
6.5
(0–23)
0.025 11
(3–29)
96
(29.4%)
Median (IQR) unless otherwise indicated.
*p indicates significance of Kruskal-Wallis test (for continuous variables) or Fisher’s exact test (for categorical variables).
†Of the 26 patients who had previously received immunosuppressant therapy, in 2 patients this was for cancer.
‡86 patients had a sPAP/RVSP value assumed to be normal and thus not measured. If those cases are omitted, only 38 values of sPAP/RVSP are missing (11.7%). Median values are
‘falsely’ high because calculation omits unmeasured (normal) values.
§Renal involvement is defined as renal crisis and/or moderate-to-severe renal impairment.
¶Despite the significant p-value for the Kruskal-Wallis test, post hoc tests reject any between-group differences in the SF36 mental scores.
** Cochin hand function scores were not performed in all centres because of translational issues.
CRP, C reactive protein; DLCO, carbon monoxide diffusing capacity; eGFR, estimated glomerular filtration rate; ESR, erythrocyte sedimentation rate; FACIT, Functional Assessment of
Chronic Illness Therapy; FVC, forced vital capacity; GI, gastrointestinal; HAQ-DI, Health Assessment Questionnaire Disability Index; mRSS, modified Rodnan skin score (17 sites); RVSP, right
ventricular systolic pressure; SF36, Short-Form 36; sPAP, systolic pulmonary artery pressure.
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conﬁrms the relative effectiveness of cyclophosphamide in
patients with pulmonary ﬁbrosis.25 26
An important point when interpreting our ﬁndings (and
therefore a note of caution) is that the ‘no immunosuppressant’
group was not a control group. Patients in this group had a
longer disease duration than the other three groups and were
more likely to have renal involvement.
Our ﬁndings lend support to two recently published studies
(the Autologous Stem Cell Transplantation International
Scleroderma trial (ASTIS) trial of autologous stem cell trans-
plantation27 and the Scleroderma Lung Study (SLS) II (compar-
ing MMF and cyclophosphamide),26 which suggest beneﬁt,
including in mRSS, from immunosuppression (as did SLS 125).
In ASTIS, those patients randomised to cyclophosphamide had
an 8.8 unit fall in mRSS (from 25.8) at 24 months (compared
with 3.3 in ESOS over 12 months), but the cyclophosphamide
protocol was more intense, and the patients had more severe
disease (patients with the highest mRSS at baseline tend to
improve most quickly4 as also demonstrated by our own ﬁnd-
ings (table 2)). MRSS fell by 19.9 units in those patients
randomised to stem cell transplantation27 (and therefore inten-
sive immunosuppression). In SLS 1,25 patients with dcSSc ran-
domised to cyclophosphamide experienced a 5.3 unit fall in
mRSS at 12 months (compared with 3.3 in ESOS), whereas
mRSS fell by 1.7 on placebo (compared with 2.2 units in the
ESOS ‘no immunosuppressant’ group). In SLS II,26 mRSS at
24 months fell 4.9 units on MMF (compared with 4.1 units in
ESOS at 12 months) and by 5.4 after 12 months treatment with
cyclophosphamide, although these values are not directly com-
parable because they relate to patients with limited cutaneous
and dcSSc combined.
The methodological strength of ESOS, which built upon
experience gained in a previous, smaller observational study,28
was its design: its standardised protocols emulated the condi-
tions of a clinical trial, and although not randomised, patients
were enrolled into four homogenous treatment arms with well-
deﬁned interventions and a systematic record of protocol
changes and exits. Entry criteria were deliberately inclusive:
RCTs often exclude patients with internal organ involvement
and for whom immunosuppression is most likely to be
Table 2 Associations between baseline characteristics and skin score
Characteristic (A) Association with baseline mRSS (B) Effect on mRSS evolution
Baseline predictor coefficient
(95% CI) p(1)
Time slope
(12 months)
Time–predictor interaction coefficient
(95% CI) p(2)
Age, per 10 years 0.9 (0.3 to 1.6) 0.004 −1.8 −0.3 (−0.6 to −0.1) 0.007
Female −1.8 (−3.7 to 0.2) 0.072 −3.5 0.1 (−0.5 to 0.8) 0.680
Months since onset of skin thickening −0.1 (−0.2 to 0) 0.156 −4.3 0.1 (0 to 0.1) 0.002
Previous immunosuppressant use −2.1 (−5.3 to 1.2) 0.205 −3.5 0.1 (−1 to 1.3) 0.808
Current or previous steroid use 1.2 (−0.6 to 3.0) 0.191 −2.9 −1.2 (−1.8 to −0.6) <0.0005
mRSS (0–51), per 5 units 0.9 −1 (−1.2 to −0.8) <0.0001
White blood count (×109/L) 0.5 (0.2 to 0.8) 0.002 −2.2 −0.1 (−0.3 to 0) 0.014
ESR (mm/hour) 0.1 (0 to 0.1) 0.003 −4.0 0 (0 to 0) 0.079
CRP (mg/L) 0.1 (0 to 0.2) 0.003 −4.4 0.1 (0 to 0.1) 0.001
Anti-topoisomerase (anti-Scl70) −2.6 (−4.4 to −0.8) 0.005 −4.3 2.2 (1.6 to 2.8) <0.0001
Anti-RNA polymerase III 4.5 (2.1 to 6.9) <0.0005 −3.0 −2.1 (−2.9 to −1.2) <0.0001
Anticentromere −0.4 (−3.9 to 3.1) 0.816 −3.4 0.5 (−0.8 to 1.9) 0.456
Organ involvement
Pulmonary fibrosis 2.9 (0.4 to 5.4) 0.021 −3.5 0.3 (−0.6 to 1.2) 0.534
FVC (% predicted) −0.1 (−0.1 to 0) 0.013 −5.5 0 (0 to 0) 0.005
DLCO (% predicted) 0 (−0.1 to 0) 0.105 −3.2 0 (0 to 0) 0.689
Pulmonary hypertension 2.5 (−0.7 to 5.8) 0.128 −3.3 −2.1 (−3.3 to −0.8) 0.001
Cardiac involvement 2.5 (−0.2 to 5.2) 0.075 −3.5 0 (−1.0 to 0.9) 0.929
Renal involvement* 2.2 (−0.7 to 5.2) 0.140 −3.3 −1.6 (−2.6 to −0.5) 0.004
Any GI involvement, no. (%) 2.2 (0.3 to 4.0) 0.021 −3.4 −0.1 (−0.8 to 0.5) 0.664
Muscle involvement 1.2 (−1.8 to 4.2) 0.425 −3.2 −2 (−2.9 to −1.0) <0.0005
Current digital ulcers 2.5 (0.1 to 4.8) 0.038 −3.3 −0.9 (−1.8 to 0) 0.047
Patient questionnaire data
HAQ-DI (0–3) 3.5 (2.5 to 4.6) <0.0001 −3.0 −0.4 (−0.8 to 0) 0.039
FACIT fatigue score (0–52), per 10 units −1.3 (−2.0 to −0.6) <0.0005 −3.1 −0.1 (−0.3 to 0.2) 0.484
SF36 physical score (0–100) −0.2 (−0.3 to −0.1) <0.0001 −3.3 0 (0 to 0) 0.873
SF36 mental score (0–100) 0.1 (−0.1 to 0.2) 0.297 −1.8 0 (−0.1 to 0) 0.081
Cochin hand function score (0–90), per
10 units
1.4 (0.9 to 1.9) <0.0001 −3.7 0 (−0.2 to 0.2) 0.979
Example for interpretation of results: the presence of anti-RNA polymerase III is associated with (A) a higher mRSS by 4.5 units at baseline and (B) losing an extra 2.1 units per year
compared with an average of −3.0 units per year for all patients.
*Renal involvement is defined as renal crisis and/or moderate-to-severe renal impairment.
p(1): Significance p value for characteristic coefficient in linear regression of baseline mRSS on baseline predictor.
p(2): Significance p value for interaction coefficient between time and baseline characteristic in a longitudinal regression model.
CRP, C reactive protein; DLCO, carbon monoxide diffusing capacity; ESR, erythrocyte sedimentation rate; FACIT, Functional Assessment of Chronic Illness Therapy; FVC, forced vital
capacity; GI, gastrointestinal; HAQ-DI, Health Assessment Questionnaire Disability Index; mRSS, modified Rodnan skin score (17 sites); SF36, Short-Form 36.
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Table 3 Predicted yearly changes in outcomes and survival rates according to initial protocol, with and without adjusting (95% CI)
Outcome Model specification p Value Methotrexate Mycophenolate mofetil Cyclophosphamide No immunosuppressant
mRSS (0–51) No adjusting, n=326 0.252 −4.4
(−5.7 to −3.2)
−3.8
(−4.9 to −2.8)
−3.5
(−5.0 to −2.0)
−2.4
(−3.9 to −1)
Adjusting for confounding (weighted model), n=326 0.346 −4.0
(−5.2 to −2.7)
(n=65)
−4.1
(−5.3 to −2.9)
(n=118)
−3.3
(−4.9 to −1.7)
(n=87)
−2.2
(−4.0 to −0.3)
(n=56)
FVC (% predicted) No adjusting, n=307 0.045 −1.7
(−4.4 to 1.0)
2.1
(−0.1 to 4.3)
4.0
(0.5 to 7.5)
2.7
(−0.8 to 6.2)
Adjusting for confounding (weighted model), n=307 0.460 −0.5
(−3.7 to 2.6)
(n=59)
2.0
(−0.7 to 4.6)
(n=111)
3.3
(−0.6 to 7.2)
(n=84)
2.0
(−1.6 to 5.6)
(n=53)
Subset with PF on HRCT, weighted, n=129† 0.035 −2.0
(−5.9 to 2.0)
(n=19)
3.2
(−0.6 to 7.0)
(n=31)
7.4
(2.2 to 12.7)
(n=57)
4.0
(−1 to 9.0)
(n=22)
DLCO (% predicted) No adjusting, n=291 0.703 −1.2
(−3.5 to 1.0)
0.3
(−1.7 to 2.3)
0.6
(−2.0 to 3.3)
−0.3
(−4.2 to 3.7)
Adjusting for confounding (weighted model), n=291 0.505 −1.6
(−3.8 to 0.6)
(n=51)
0.8
(−1.5 to 3.1)
(n=110)
0.1
(−3.1 to 3.2)
(n=79)
−0.1
(−3.7 to 3.4)
(n=51)
Subset with PF on HRCT, weighted, n=116† 0.809 −0.8
(−5.4 to 3.8)
(n=12)
1.9
(−1.8 to 5.6)
(n=31)
1.8
(−1.9 to 5.4)
(n=53)
1.6
(−2.6 to 5.7)
(n=20)
HAQ-DI (0–3) No adjusting, n=307 0.070 −0.1
(−0.2 to 0.1)
0
(−0.1 to 0.1)
−0.2
(−0.3 to −0.1)
0.1
(−0.1 to 0.2)
Adjusting for confounding (weighted model), n=307 0.130 −0.1
(−0.3 to 0)
(n=59)
0
(−0.1 to 0.1)
(n=113)
−0.1
(−0.3 to 0)
(n=81)
0.1
(−0.1 to 0.2)
(n=54)
Cochin hand function (0–90)‡ No adjusting, n=230 0.072 −1.1
(−3.5 to 2.2)
−0.3
(−1.6 to 1.2)
−3.1
(−5.1 to −0.5)
1.1
(−0.3 to 3.0)
Adjusting for confounding (weighted model), n=230 0.073 −1.4
(−3.5 to 1.4)
(n=36)
−0.6
(−2.0 to 1.1)
(n=103)
−2.4
(−4.7 to 0.6)
(n=49)
1.7
(-0.1 to 4.0)
(n=42)
Survival No adjusting, n=326 0.389 (12 months) 93.5%
(24 months) 93.5%
(12 months) 96.5%
(24 months) 89.3%
(12 months) 88.1%
(24 months) 85.4%
(12 months) 88.9%
(24 months) 85.1%
Adjusting for confounding
(weighted model), n=326
0.440 (12 months) 94.1%
(24 months) 94.1%
(12 months) 96.1%
(24 months) 88.8%
(12 months) 91.7%
(24 months) 90.1%
(12 months) 88.6%
(24 months) 84.0%
Significance p: Fisher’s test for equality of change rates between protocols, for each outcome variable.
*Results are reported in terms of changes after 12 months. However, all study data (from baseline to the 24-month end point) were used in estimation. To obtain 24-month changes, multiply results above by 2.
†For the subanalysis involving the subset of patients with pulmonary fibrosis at baseline, patients with definite bibasal pulmonary fibrosis confirmed on HRCT were included, irrespective of FVC value. If no HRCT scan was performed at baseline, an
FVC<55%, DLCO<55% predicted or definite bibasal shadowing on X-ray was also a basis for inclusion.
‡Changes expressed in units for the Cochin regression are an approximation derived from the 95% CI of percentage changes between baseline and 12 months (on a scale shifted by one unit), applied to the predicted baseline values for each group in the
original scale.
DLCO, carbon monoxide diffusing capacity; FVC, forced vital capacity; HAQ-DI, Health Assessment Questionnaire Disability Index; HRCT, high-resolution CT; mRSS, modified Rodnan skin score (17 sites); PF, pulmonary fibrosis.
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Figure 2 Modiﬁed Rodnan skin score (mRSS) during baseline and follow-up visits, by initial protocol. For each group of patients, according to their
initial protocol, the distribution of the skin score is illustrated on the left-hand side by box and whisker plots (indicating the median and IQR) at
baseline, 12 and 24 months. On the right-hand side, the distribution of individual 1-year changes in the skin score is described by histograms and a
kernel density estimate. In addition, a vertical green line indicates the value of the average 1-year change in the skin score, irrespective of treatment
choice. The bottom panel in the ﬁgure describes the estimated changes in mRSS (with 95% CI) according to initial protocol, based on the results
from the adjusted model (described in table 3).
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beneﬁcial. By recruiting 326 patients from 50 centres, ESOS
represents a large cohort of patients with very early dcSSc
(median duration of skin thickening 11.9 months): its data will
serve as a benchmark when designing and interpreting future
clinical trials. This is especially relevant with a number of novel
treatment approaches currently being explored including bio-
logical agents. For example, in a recent RCT of tocilizumab,29
mRSS fell over 24 weeks by 3.9 units from 26 in the 43
tocilizumab-treated patients and by 1.2 units from 26 in the 44
placebo-treated patients, this latter fall comparable to the ESOS
‘no immunosuppressant’ response. In comparing between these
studies, the higher baseline mRSS in the tocilizumab study
should be borne in mind.
The main weakness of observational studies is that each
patient’s outcome on her/his treatment arm cannot be com-
pletely disentangled from her/his initial characteristics. For
instance, ESOS has veriﬁed that patients with lung and cardiac
involvement tend to be prescribed cyclophosphamide. However,
adjusting using IPTweights minimises the problem of confound-
ing by indication.
In conclusion, observational studies offer a rich population-
wide perspective assessing treatment effects in a real-world
setting. ESOS achieved its aim of following a large international
cohort of patients with early dcSSc over 2 years, each of whom
was treated according to one of four protocols. The message for
clinicians is that there is a weak signal to support using immuno-
suppressants for early dcSSc (and in particular cyclophospha-
mide for patients with pulmonary ﬁbrosis). However, it is clear
that there remains a pressing need for the development of more
effective and targeted treatments.
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